Groundbreaking capabilities
Microbiome. Cancer. Crohn's and Colitis.

Morphological stool data was the first step of Coprata’s advanced stool analysis. The Sampling Toilet introduces the groundbreaking capability of automated hands-free collection of stool specimen, where stool is produced, eliminating the need of any physical, visual, or olfactory interaction.

The current gold standard is manual self-collection, which is considered unpleasant by most people and results in reluctance to repeated measurements. The Coprata solution offers unprecedented access to a specimen, facilitating frequent and long-term measurement of fecal biomarkers, instead of single snapshot test.
‍
Fecal biomarkers (gut microbiome, inflammatory proteins, and others) hold promise for the prediction of disease risk and response to therapy in illnesses such as chronic digestive diseases, cancers, and infections.
‍
The Sampling Toilet will enable new types of clinical research and the development of novel approaches to proactive health. Established stool biomarkers include occult (hidden) blood detected by the Fecal Immunochemical Test (FIT), a non-invasive screening for colon cancer, and the inflammatory protein calprotectin, whose rising values predict flare-ups in Crohn's disease and ulcerative colitis. Many more biomarkers are to be discovered.

The Coprata Sampling Toilet paves the way for new medical research and discovery and represents a convenient tool to monitor specific early warning of disease and to track the effectiveness of therapies.